Video

Prostate Cancer Screening and Early Detection, Part II

In the second segment of this series on PSA screening and early-detection for men with prostate cancer, panelists Mark S. Austenfeld, MD, addresses the comments made by E. David Crawford, MD, in the first part of this series (View >>> Prostate Cancer Screening and Early Detection, Part I.

Austenfeld believes that the United States Preventive Service Task Force (USPSTF) did not make the correct recommendation for PSA screening. Austenfeld holds the position that ample evidence did not exist to recommend against PSA screening; however, he agrees with Crawford that overdiagnosis and overtreatment need to be addressed.

PSA screening can be associated with many positive statistics, such as lower death rates, Austenfeld notes. Additionally, he believes that the recommendation did not pay adequate attention to the opinions given during the advisory period, particularly those from the American Urological Association.

Crawford clarifies that he does not feel that the USPSTF decision was completely accurate and that he believes it will likely need to be adjusted, in the future. Moderator Raoul S. Concepcion, MD, adds that he believes that overtreatment and overdiagnosis should not go hand in hand and that many men deserve to know early on that they have prostate cancer, even if it does not require treatment. However, Crawford points out that once men discover that they have prostate cancer they will immediately want some type of treatment.

View >>> Prostate Cancer Screening and Early Detection, Part I

View >>> Prostate Cancer Screening and Early Detection, Part III

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity